Clinical Pharmacology Analytical Core
Access to high-end instrument for quantification of drugs and metabolites is an invaluable resource for all cancer investigators in the IUSCC. The core has four of these instruments (HPLC-MS/MS; API 5500 QTRAP, API 4000, Thermo Quantum Ultra, and API 3200) for drug quantification.
Further value added information:
- Method development and quantification of drugs. These data provide the PI with information on exposure, half-life and can be correlated with pharmacodynamic and engraftment outcomes.
- CPAC has developed analytical methods for 114 new chemical entities (NCEs); and
- CPAC has developed analytical methods for 155 clinically approved drugs
- CPAC generates pharmacokinetic data of drugs in multiple specimen types
- Plasma pharmacokinetic data provide the principal investigator (PI) with information on exposure, half-life, clearance, volume of distribution, and bioavailability.
- Tissue pharmacokinetic data provide evidence of drug exposure at the site of tumor (or disease site). In addition, this information guides the PI on exposure of drug in major organs, e.g. liver, heart, brain, kidney.
- Currently, CPAC has developed 19 methods applying Dried Blood Spot (DBS) technology. DBS technology has allowed the use of less sample, subjects are more amenable to DBS sampling, and DBS samples are much easier for storage. Good examples of this include Kenyan studies and pediatric leukemia patients where sample volume is limited.